Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HRH3 | Q9Y5N1 | 7/20 | 0.43 |
| ▸ | SIGMAR1 | Q99720 | 3/20 | 0.42 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.41 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.41 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.41 |
| ▸ | DRD2 | P14416 | 3/20 | 0.40 |
| ▸ | DRD3 | P35462 | 2/20 | 0.40 |
| ▸ | HTR1A | P08908 | 1/20 | 0.40 |
| ▸ | DRD1 | P21728 | 1/20 | 0.40 |
| ▸ | HTR2A | P28223 | 1/20 | 0.40 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.38 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.36 |
| ▸ | CACNA1I | Q9P0X4 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21899148 | 0.84 | RET (0.46) | HRH3SLC6A2SLC6A4SLC6A3DRD2 | |
| SCHEMBL20234904 | 0.83 | HRH3 (0.46) | HRH3SIGMAR1SLC6A2SLC6A4SLC6A3 | |
| SCHEMBL19959013 | 0.82 | HRH3 (0.54) | HRH3SIGMAR1SLC6A2SLC6A4SLC6A3 | |
| SCHEMBL12788390 | 0.82 | HRH3 (0.59) | HRH3SLC6A2SLC6A4SLC6A3DRD2 | |
| SCHEMBL19959003 | 0.81 | HRH3 (0.47) | HRH3SIGMAR1SLC6A2SLC6A4SLC6A3 | |
| SCHEMBL24654193 | 0.77 | HRH3 (0.44) | HRH3SIGMAR1SLC6A2SLC6A4SLC6A3 | |
| SCHEMBL24654470 | 0.71 | RET (0.45) | HRH3SLC6A2SLC6A4SLC6A3DRD2 | |
| SCHEMBL24590359 | 0.71 | POLB (0.49) | — | |
| SCHEMBL19958939 | 0.71 | ALDH1A1 (0.41) | HRH3SLC6A2SLC6A4SLC6A3DRD3 | |
| SCHEMBL20231637 | 0.70 | HDAC6 (0.46) | HRH3SIGMAR1DRD2DRD3HTR1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20200121684-A1 | MODULATORS OF BTK PROTEOLYSIS AND METHODS OF USE | UNIV YALE (US) | 2020-04-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200121684-A1 | MODULATORS OF BTK PROTEOLYSIS AND METHODS OF USE | BTK, CBL, CRBN | HRH3 3605/4885SIGMAR1 4432/4885SLC6A2 4744/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.